Identification and characterization of a cross-neutralization epitope of Enterovirus 71

Vaccine

Volumn 29, Issue 26, 2011, Pages 4362-4372

  Liu, Chia Chyi ^a   Chou, Ai Hsiang ^a   Lien, Shu Pei ^a   Lin, Hsiao Yu ^a   Liu, Shih Jen ^a,b   Chang, Jui Yuan ^a   Guo, Meng Shin ^a   Chow, Yen Hung ^a   Yang, Wun Syue ^a   Chang, Kate Hsuen Wen ^a   Sia, Charles ^a   Chong, Pele ^a,b  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Cross genotype neutralizing antibody; EV71 vaccine; Hand foot and mouth disease (HFMD); Inactivated whole virion vaccine; Potency assay development

Indexed keywords

ALUMINUM POTASSIUM SULFATE; ANTIBODIES,ANTISERA AND IMMUNOGLOBULINS; EPITOPE; FORMALDEHYDE; MONOCLONAL ANTIBODY; PROTEIN VP1; PROTEIN VP2; PROTEIN VP3; SYNTHETIC PEPTIDE; VIRUS VACCINE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENTEROVIRUS 71; ENTEROVIRUS INFECTION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; FEMALE; GENOTYPE; HAND FOOT AND MOUTH DISEASE; IMMUNOGENICITY; MOLECULAR MODEL; MOUSE; NONHUMAN; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; PROTEIN ANALYSIS; QUANTITATIVE ASSAY; RAT; SEQUENCE ALIGNMENT; VIRUS CAPSID; VIRUS NEUTRALIZATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, VIRAL; CAPSID PROTEINS; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; CROSS REACTIONS; ENTEROVIRUS; ENTEROVIRUS INFECTIONS; EPITOPE MAPPING; IMMUNODOMINANT EPITOPES; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PEPTIDES; POLIOVIRUS; RABBITS; RATS; VACCINES, INACTIVATED; VERO CELLS; VIRAL VACCINES;

EID: 79957836497     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.04.010     Document Type: Article

References (24)

1. Ho M., Chen E.R., Hsu K.H., Wu S.J.T., Chen K.T., Tsai S.F., et al. for the Taiwan Enterovirus Epidemic Working Group An epidemic of enterovirus 71 infection in Taiwan. N Engl J Med 1999, 341:929-935.
2. Lee M.S., Chang L.Y. Development of enterovirus 71 vaccines. Expert Rev Vaccines 2010, 9:149-156.
3. McMinn P.C. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev 2002, 26:91-107.
4. McMinn P.C. Enterovirus 71 in the Asia-Pacific region: an emerging cause of acute neurological disease in young children. Neurol J Southeast Asia 2003, 8:57-63.
5. Qiu J. Enterovirus 71 infection: a new threat to global public health?. Lancet Neurol 2008, 7:868-869.
6. Schmidt N.J., Lennette E.H., Ho H.H. An apparently new enterovirus isolated from patients with disease of the central nervous system. J Infect Dis 1974, 129:304-309.
7. Xu J, Qian Y, Wang S, Serrano JMG, Li W, Huang Z, et al. EV71: an emerging infectious disease vaccine target in the Far East? Vaccine; doi:10.1016/j.vaccine.2010.03.003.
8. Huang S.W., Hsu Y.W., Smith D.J., Kiang D., Tsai H.P., et al. Reemergence of enterovirus 71 in 2008 in Taiwan: dynamics of genetic and antigenic evolution from 1998 to 2008. J Clin Mincrobiol 2009, 47:3653-3662.
9. Lin K.H., Hwang K.P., Ke G.M., Wang C.F., Ke L.Y., Hsu Y.T., et al. Evolution of EV71 genogroup in Taiwan from 1998 to 2005: an emerging of subgenogroup C4 of EV71. J Med Virol 2006, 78:254-262.
10. Brown B.A., Pallansch M.A. Complete nucleotide sequence of enterovirus 71 is distinct from poliovirus. Virus Res 1995, 39:195-205.
11. Chen H.L., Huang J.Y., Chu T.W., Tsai T.C., Hung C.M., et al. Expression of VP1 protein in the milk of transgenic mice: a potential oral vaccine protects against enterovirus 71 infection. Vaccine 2008, 26:2882-2889.
12. Ong K.C., Devi S., Cardosa M.J., Wong K.T. Formaldehyde-inactivated whole-virus vaccine protects a murine model of enterovirus 71 encephalomyetitis against disease. J Virol 2010, 84:661-665.
13. Tung W.S., Bakar S.A., Sekawi Z., Rosli R. DNA vaccine constructs against enterovirus 71 elicit immune response in mice. Genet Vaccines Ther 2007, 5:6.
14. Wu S.C., Liu C.C., Lian W.C. Optimization of microcarrier cell culture process for the inactivated enterovirus type 71 vaccine development. Vaccine 2004, 22:3858-3864.
15. Chung Y.C., Ho M.S., Wu J.C., Chen W.J., Huang J.H., Chou S.T., et al. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine 2008, 26:1855-1862.
16. Nishimura Y., Shimojima M., Tano Y., Miyamura T., Wakita T., Shimizu H. Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Mat Med 2009, 15:794-797.
17. Yamayoshi S., Yamashita Y., Li J., Hanagata N., Minowa T., Takemura T., et al. Scavenger receptor B2 is a cellular receptor for enterovirus 71. Mat Med 2009, 15:798-801.
18. Sung J.W.C., Hsieh S.Y., Lin C.L., Leng C.H., Liu S.J., Chou A.H., et al. Biochemical characterization of E. coli expressed protective antigen Ag473 of N. meningitides group B. Vaccine 2010, 09091. 10.1016/j.vaccine.2010.
19. Reed L.J., Muench h. A simple method of estimating 50 percent end-points. Am J Hyg 1938, 27:493-497.
20. Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256:495-497.
21. Panezutti H., James O., Hansen E.J., Choi Y., Harkness R.E., Klein M.H., et al. Identification of surface-exposed B-cell epitopes recognized by H Influenzae type b P1-specific monoclonal antibody. Infect Immun 1993, 61:1867-1872.
22. Foo D.G., Alonso S., Phoon M.C., Ramachandran N.P., Chow V.T., Poh C.L. Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides. Virus Res 2007, 125:61-68.
23. Guang D.M., Foo W., Alonso S., Chow V.T.K., Poh C.L. Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes Infect 2007, 9:1299-1306.
24. Rossmann M.G. The Canyon Hypothesis: hiding the host cell receptor attachment site on a viral surface from immune surveillance. J Biol Chem 1989, 264:14587-14590.